Amita Gupta's extensive tuberculosis drug trial, involving nearly 6,000 participants across 13 countries, faces termination due to a new NIH policy banning 'foreign subawards.' This abrupt change threatens the funding for many ongoing experimental drug trials and jeopardizes participant care. Affected researchers, concerned about wasted taxpayer investments and the welfare of trial participants, argue that the NIH's rationale of national security risks undermining essential research efforts. The sudden halt poses challenges to both the scientists and the individuals relying on the studies for care and treatment.
This trial is the product of five years of formative work that American taxpayers have invested in, and they will never know the results of this study that they've paid for.
Since the policy was disclosed, NIH employees have been forbidden from issuing grants involving such awards, according to internal documents that Nature has obtained.
Collection
[
|
...
]